FGF21 and sarcopenia: The animal-based studies and several substudies of clinical trials on sarcopenia that we have reviewed so far have found that muscle-dependent elevations of FGF21 may be associated with muscle aging, myocyte atrophy, and FGF 21 was once proposed as a specific serum candidate marker for sarcopenia [14-16].